Progress in research and development related to CT-01 project

Current Report No. 12/2022

Date of preparation: 19 April 2022

Subject: Progress in research and development related to CT-01 project

Legal basis: Art. 17(1) of MAR – inside information

The Management Board of Captor Therapeutics S.A., with its registered office in Wroclaw (the "Company"), with reference to the current report no. 3/2022 and no. 11/2022, in which the Company provided information concerning progress in research and development related to the project CT-01 (the "Project") and about the molecular targets of the Project, which is focused on the development of targeted protein degradation therapy for hepatocellular carcinoma, hereby announces further significant scientific progress in the Project.

The Company obtained results of additional in-vivo studies that confirm the potent antitumor activity of two CT-01 lead compounds in a liver cancer mouse xenograft model. These new results demonstrate that oral administration of these CT-01 candidates causes complete disappearance (regression) of hepatocellular carcinoma tumors in a mouse model of Hep3B2.1-7.

The study was designed to establish the miniml effective dose of the two drug candidates. High levels of compound activity were observed at all reported concentrations for compound A where the minimum concentration was 10 mg/kg body weight and at concentrations in the range of 100, 50 and 25 mg/kg for compound B.  The full efficacy obtained at low doses decreases risk of potential treatment-related adverse effects. 

This preclinical data represents a significant milestone and supports the further advancement of the Captor’s candidates towards IND-enabling studies. Simultaneously, these results demonstrate the capability of the Company to rationally discover and optimise molecular glue-type degraders using its Optigrade^TM platform.

The Company will inform about further progress in CT-01 project in accordance with legal requirements.